Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 28.

Journal Article

Althoff, K., Leitzke, S., Herling, C., Frenzel, L., Schiller, J., Herling, M., Holtick, U., Scheid, C. and Theurich, S. (2018). Metabolic status and immune activation prior conditioning influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation. Oncol. Res. Treat., 41. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262

Becker, H. J., Reuter, S., Marquez, Garcia M., Schloesser, H. A., von Bergwelt-Baildon, M. and Theurich, S. (2016). B cells derived from patients with von Hippel-Lindau (VHL) disease display impaired antigen presentation upon CD40 activation. Oncol. Res. Treat., 39. S. 271 - 272. BASEL: KARGER. ISSN 2296-5262

Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M. and Scheid, C. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience. Ann. Hematol., 94 (10). S. 1717 - 1726. NEW YORK: SPRINGER. ISSN 1432-0584

Holtick, U., Frenzel, L., Froehlich, H., Shimabukuro-Vornhagen, A., Theurich, S., Claasen, J., Scheid, C., von Bergwelt-Baildon, M., Wendtner, C. and Chemnitz, J. (2014). INCREASED FUNCTIONAL T CELL DEFECTS IN PATIENTS WITH LOW CD4 COUNTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Bone Marrow Transplant., 49. S. S558 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Holtick, U., Herling, M., Theurich, S., Frenzel, L., Herling, C., Schiller, J., Hallek, M. and Scheid, C. (2018). A phase II study to investigate the efficacy of short-term everolimus in addition to post-transplant cyclophosphamide as graft-versus-host-prophylaxis after allogeneic hematopoietic stem cell transplantation (OCTET-EVER). Oncol. Res. Treat., 41. S. 63 - 64. BASEL: KARGER. ISSN 2296-5262

Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Huelsemann, M., Baatout, D., Kintzele, L., Becker, H. J., Theurich, S., von Berwelt-Baildon, M., Pallasch, C. P., Hallek, M., Wendtner, C. M. and Frenzel, L. P. (2014). HYPOXIA - A CENTRAL MICROENVIRONMENTAL DETERMINANT OF PROLIFERATION AND DRUG-RESISTANCE OF PRIMARY CLL CELLS. Haematologica, 99. S. 39 - 41. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Huelsemann, M. F., Patz, M., Beckmann, L., Brinkmann, K., Otto, T., Fandrey, J., Becker, H. J., Theurich, S., von Bergwelt-Baildon, M., Pallasch, C. P., Zahedi, R. P., Kashkar, H., Reinhardt, H. C., Hallek, M., Wendtner, C. M. and Frenzel, L. P. (2015). Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 29 (4). S. 981 - 985. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Huelsemann, M. F., Patz, M., Beckmann, L., Brinkmann, K., Otto, T., Fandrey, J., Becker, H. J., Theurich, S., von Bergwelt-Baildon, M., Pallasch, C. P., Zahedi, R. P., Kashkar, H., Reinhardt, H. C., Hallek, M., Wendtner, C. M. and Frenzel, L. P. (2015). Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 29 (4). S. 981 - 985. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Huelsemann, M. F., Theurich, S., Becker, H. J., Pallasch, C., von Bergwelt-Baildon, M., Hallek, M., Wendtner, C. -M and Frenzel, L. P. (2014). p38 controls sensitivity to BH3 mimetics in CLL via regulation of Mcl-1. Oncol. Res. Treat., 37. S. 222 - 223. BASEL: KARGER. ISSN 2296-5262

Koenigsmann, M., Casper, J., Kahl, C., Basara, N., Sayer, H. G., Behre, G., Theurich, S., Christopeit, M., Mohren, M., Reichle, A., Metzner, B., Ganser, A., Stadler, M., Uharek, L., Balleisen, L., Hinke, A., Hinke, R. and Niederwieser, D. (2014). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant., 49 (3). S. 410 - 416. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Pflug, N., Chakupurakal, G., Theurich, S., Holtick, U., Leitzke, S., Chemnitz, J., Scheid, C., Hallek, M. and von Bergwelt-Baildon, M. (2018). Addition of rituximab to nonmyeloablative allogeneic transplantation for CLL and Richter's transformation - a single center experience. Oncol. Res. Treat., 41. S. 102 - 103. BASEL: KARGER. ISSN 2296-5262

Pflug, N., Vitus, M., Knuever, J., Hamacher, S., Mauch, C., Schlaak, M. and Theurich, S. (2021). Treatment-specific evaluation of the modified Glasgow-Prognostic-Score in patients with advanced cutaneous melanoma. J. Eur. Acad. Dermatol. Venereol., 35 (12). S. E879 - 5. HOBOKEN: WILEY. ISSN 1468-3083

Scheid, C., Chemnitz, J., Herling, M., Pflug, N., Theurich, S., Burst, A., Leitzke, S., von Bergwelt-Baildon, M., Hallek, M. and Holtick, U. (2016). A ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL AGENTS FOR HODGKIN'S LYMPHOMA? Haematologica, 101. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Schlaak, M., Kurschat, P., Shimabukuro-Vornhagen, A., Scheid, C., Chemnitz, J., Stadler, R., von Bergwelt-Baildon, M. and Theurich, S. (2011). Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl. Immunol., 25 (2-3). S. 163 - 167. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 0966-3274

Schloesser, H. A., Thelen, M., Lechner, A., Gilles, R., Garcia-Marquez, M., Wennhold, K., Alakus, H., Schroeder, W., Moenig, S., Theurich, S., Shimabukuro-Vornhagen, A., Gathof, B., Drebber, U., Quaas, A., Bruns, C., Hoelscher, A. H. and von Bergwelt-Baildon, M. (2017). Tumor-associated B cells and humoral immune response in esophago-gastric adenocarcinoma. Oncol. Res. Treat., 40. S. 159 - 160. BASEL: KARGER. ISSN 2296-5262

Stranzenbach, R., Theurich, S. and Schlaak, M. (2017). Role of stem cell transplantation in treatment of primary cutaneous T-cell lymphoma. Hautarzt, 68 (9). S. 716 - 721. NEW YORK: SPRINGER. ISSN 1432-1173

Theurich, S., Becker, H. J., Malcher, J., Marquez, M. G., Wennhold, K., Reuter, S., Shimabukuro-Vornhagen, A., Schloesser, H. A., Huelsemann, M., Frenzel, L. P. and von Bergwelt-Baildon, M. (2017). Hypoxia and iron-chelation decrease antigen-presenting functions in CD40-activated human B cells. Oncol. Res. Treat., 40. S. 255 - 256. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Gerecht, L., Naetlitz, J., Borggrefe, J., Zopfs, D., dos Santos, Pinto D. and Schlaak, M. (2018). Body-composition analyses in melanoma patients that undergo anti-PD-1 immunotherapy - a prospective observational pilot study. Oncol. Res. Treat., 41. S. 304 - 306. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Iltgen, J., Wennhold, K., Marquez, M. Garcia, Rothschild, S., Schneider, B., Holtick, U., Thelen, M., Scheid, C., Becker, Hj, Schloesser, H., Reuter, S., Vornhagen, A. Shimabukuro and von Bergwelt-Baildon, M. (2016). THE JAK1/2 INHIBITOR RUXOLITINIB MODULATES ANTIGEN PRESENTING FUNCTIONS OF ACTIVATED PRIMARY B CELLS ON A METABOLIC LEVEL. Haematologica, 101. S. 462 - 463. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Theurich, S., Iltgen-Brebuda, J., Thelen, M., Wennhold, K., Rothschild, S., Becker, H., Schloesser, H., Shimabukuro-Vornhagen, A. and von Bergwelt-Baildon, M. (2017). Ruxolitinib modulates the antigen presenting function of activated B cells by interfering with metabolic pathways. Oncol. Res. Treat., 40. S. 262 - 263. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Mueller, P., Martin, K., Savic, S., Terszowski, G., Lardinois, D., Schlaak, M., Stadler, R., Kvasnicka, H. -M., Spagnoli, G., Dirnhofer, S., Speiser, D. E., von Bergwelt-Baildon, M. and Zippelius, A. (2014). Beyond cytotoxicity: Implications for immune mediated mechanisms of action of brentuximab vedotin treatment in CD30(+) lymphomas. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Rothschild, S. I., Hoffmann, M., Fabri, M., Sommer, A., Marquez, M. Garcia, Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., von Bergwelt-Baildon, M. and Schlaak, M. (2016). Cytotoxic local tumor treatment in combination with xystemic Ipilimumab enhances the efficacy of this immunotherapy and prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Rothschild, S., I, Hoffmann, M., Fabri, M., Sommer, A., Garcia-Marquez, M., Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., Borggrefe, J., Schlaak, M. and von Bergwelt-Baildon, M. (2016). Local treatment of tumors or metastases in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 103 - 105. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Rabenhorst, A., Hartmann, K., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Exp. Dermatol., 23 (3). S. E25 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625

Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262

Trommer-Nestler, M., Yeo, S. Y., Marnitz, S., Persigehl, T., Bunck, A., Schlaak, M., Gruell, H., Theurich, S., von Bergwelt-Baildon, M., Herter, J., Celik, E., Rosenbrock, J. and Baues, C. (2018). Abscopal effects in metastasized cancer patients treated with PD-1 inhibition and radiation therapy. Strahlenther. Onkol., 194. S. S200 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X

This list was generated on Thu Mar 28 12:47:57 2024 CET.